Advanced search
Publication Cover
Clinical, Cosmetic and Investigational Dermatology Volume 14, 2021 - Issue
Submit an article Journal homepage
125
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Use of Methotrexate in the Treatment of Moderate to Severe Plaque Psoriasis in France: A Practice Survey

Anne-Claire Fougerousse1 Dermatology Department, Hôpital d’Instruction des Armées Bégin, Saint Mandé, 94160, FranceCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2850-867X
ORCID Icon,
Laure Mery-Bossard2 Dermatology Department, Centre Hospitalier Intercommunal Poissy Sant Germain en Laye, Saint-Germain-en-Laye, 78100, France
,
Josiane Parier3 Private Practice, La Varenne Saint Hilaire, Saint-Maur-des-Fossés, 94210, France
,
Charles Taieb4 European Market Maintenance Assessment, Patients Priority Department, Fontenay sous-Bois, FranceORCID Iconhttps://orcid.org/0000-0002-5142-2479
ORCID Icon,
Antoine Bertolotti5 Infectious Diseases and Dermatology Department, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, La Réunion, France;6 Inserm CIC1410, Centre Hospitalier Universitaire de la Réunion, Saint Pierre, La Réunion, France
,
Francois Maccari3 Private Practice, La Varenne Saint Hilaire, Saint-Maur-des-Fossés, 94210, France
& On behalf of GEM ResoPso show all
Pages 389-393 | Published online: 23 Apr 2021

References

  • Richard MA, Corgibet F, Beylot-Barry M, et al. Sex- and age-ajusted prevalence estimates of five chronic inflammatory skin diseases in France: results of the OBJECTIFS PEAU study. J Eur Acad Dermatol Venereol. 2018;32:1967–1971. doi:10.1111/jdv.14959
  • Mrowietz U, Kragballe K, Reich K, et al. Definition of treatment goals for moderate to severe psoriasis: a European consensus. Arch Dermatol Res. 2011;303(1):1–10. doi:10.1007/s00403-010-1080-1
  • Amatore F, Villani AP, Tauber M, Viguier M, Guillot B; Psoriasis Research Group of the French Society of Dermatology (Groupe de Recherche sur le Psoriasis de la Société Française de Dermatologie). French guidelines on the use of systemic treatments for moderate-to-severe psoriasis in adults. J Eur Acad Dermatol Venereol. 2019;33(3):464–483. doi:10.1111/jdv.15340
  • Gyulai R, Bagot M, Griffiths CEM, et al. Current practice of méthotrexate use for psoriasis: results of a worldwide survey among dermatologists. J Eur Acad Dermatol Venereol. 2015;29(2):224–231. doi:10.1111/jdv.12495
  • Mazzuoccolo LD, Luna PC, Marciano S, et al. Real world prescription trends of méthotrexate for psoriasis in Argentina: results of a national survey. J Dermatolog Treat. 2017;28(7):631–634. doi:10.1080/09546634.2017.1329503
  • Menting SP, Dekker PM, Limpens J, Hooft L, Spuls PI. Methotrexate dosing regimen for plaque-type psoriasis: a systematic review of the use of test-dose, start-dose, dosing scheme, dose adjustments, maximum dose and folic acid supplementation. Acta Derm Venereol. 2016;96(1):23–28. doi:10.2340/00015555-2081
  • Menter A, Gelfand JM, Connor C, et al. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020;82(6):1445–1486. doi:10.1016/j.jaad.2020.02.044
  • Tournier A, Khemis A, Maccari F, et al. Methotrexate efficacy and tolerance in plaque psoriasis. A prospective real-life multicentre study in France. Ann Dermatol Venereol. 2019;146(2):106–114. doi:10.1016/j.annder.2018.11.011
  • Reich K, Sorbe C, Griese L, Reich JLK, Augustin M. The value of subcutaneous vs. oral méthotrexate: real-world data from the German psoriasis registry PsoBest. Br J Dermatol. 2020. doi:10.1111/bjd.19690.
  • Warren RB, Weatherhead SC, Smith CH, et al. British Association of Dermatologists’ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. Br J Dermatol. 2016;175(1):23–44. doi:10.1111/bjd.14816
  • Montaudié H, Sbidian E, Paul C, et al. Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol. 2011;25(Suppl 2):12–18. doi:10.1111/j.1468-3083.2011.03991.x
  • Maybury CM, Jabbar-Lopez ZK, Wong T, Dhillon AP, Barker JN, Smith CH. Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol. 2014;171(1):17–29. doi:10.1111/bjd.12941
  • Fougerousse AC, Perrussel M, Bécherel PA, et al. Systemic or biologic treatment in psoriasis patients does not increase the risk of a severe form of COVID-19. J Eur Acad Dermatol Venereol. 2020;34(11):e676–e679. doi:10.1111/jdv.16761
  • Chiricozzi A, Gisondi P, Bellinato F, Girolomoni G. Immune response to vaccination in patients with psoriasis treated with systemic therapies. Vaccines (Basel). 2020;8(4):769. doi:10.3390/vaccines8040769

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.